Axon Enterprise (NASDAQ:AXON) Stock Keeps “Overweight” Rating at Piper Sandler

Axon Enterprise (NASDAQ:AXON)‘s stock had its “overweight” rating reiterated by research analysts at Piper Sandler in a research report issued on Friday, Benzinga reports. They presently have a $540.00 price objective on the biotechnology company’s stock, down from their prior price objective of $561.00. Piper Sandler‘s target price suggests a potential upside of 41.15% from the company’s previous close.

AXON has been the topic of several other reports. Morgan Stanley upped their price target on shares of Axon Enterprise from $600.00 to $640.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. The Goldman Sachs Group decreased their price objective on shares of Axon Enterprise from $715.00 to $675.00 and set a “buy” rating for the company in a research note on Monday, September 21st. Zacks Research lowered Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Barclays upped their target price on Axon Enterprise from $523.00 to $688.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Finally, Argus increased their price target on Axon Enterprise from $460.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday, September 3rd. Thirteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $644.56.

Axon Enterprise Trading Down 9.8%

AXON stock opened at $382.56 on Friday. The company has a quick ratio of 1.80, a current ratio of 2.15 and a debt-to-equity ratio of 0.47. Axon Enterprise has a twelve month low of $339.01 and a twelve month high of $665.07. The stock has a market capitalization of $31.08 billion, a price-to-earnings ratio of 158.74, a price-to-earnings-growth ratio of 8.06 and a beta of 1.48. The firm’s fifty day simple moving average is $447.49 and its two-hundred day simple moving average is $476.73.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Friday, November 6th. The biotechnology company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.89 by ($0.17). The firm had revenue of $908.55 million during the quarter, compared to analysts’ expectations of $934.33 million. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The company’s revenue was up 27.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.17 EPS. As a group, analysts anticipate that Axon Enterprise will post 2.10 earnings per share for the current year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, insider Jeffrey C. Kunins sold 9,605 shares of the business’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $626.70, for a total value of $6,019,453.50. Following the completion of the sale, the insider directly owned 97,761 shares of the company’s stock, valued at $61,266,818.70. The trade was a 8.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Joshua Isner sold 16,775 shares of the business’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $574.43, for a total transaction of $9,636,063.25. Following the completion of the sale, the president directly owned 296,974 shares of the company’s stock, valued at approximately $170,590,774.82. This trade represents a 5.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 37,397 shares of company stock worth $21,234,034. 4.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Axon Enterprise

A number of institutional investors have recently modified their holdings of the stock. State Street Corp increased its holdings in Axon Enterprise by 5,700.2% during the 2nd quarter. State Street Corp now owns 213,561,844 shares of the biotechnology company’s stock worth $119,724,905,000 after purchasing an additional 209,879,882 shares during the period. Envestnet Asset Management Inc. raised its position in Axon Enterprise by 18,050.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 13,200,075 shares of the biotechnology company’s stock valued at $7,400,094,000 after purchasing an additional 13,127,348 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its holdings in shares of Axon Enterprise by 391,214.9% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 6,988,884 shares of the biotechnology company’s stock worth $2,952,943,000 after buying an additional 6,987,098 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Axon Enterprise by 5,022.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 4,266,589 shares of the biotechnology company’s stock worth $1,802,719,000 after buying an additional 4,183,302 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Axon Enterprise by 8,432.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,537,957 shares of the biotechnology company’s stock worth $1,983,414,000 after buying an additional 3,496,493 shares during the period. 79.08% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon reported record Q3 revenue of about $909 million, up 28% year over year, and returned to profitability. Drone-as-First-Responder revenue rose 43%, while AI bookings were up more than 50% year to date and AI annual recurring revenue topped $100 million. Read More.
• Positive Sentiment: Axon is investing an additional $1.2 billion in Skydio, bringing its stake to 37%, and will become Skydio’s exclusive public-safety distributor in the U.S. and Canada. The deal could strengthen Axon’s position in drones and related services, though it also represents a substantial investment. Read More.
• Neutral Sentiment: Needham cut its price target from $750 to $500 but retained a Buy rating. Goldman Sachs and JPMorgan also lowered their targets, to $575 and $610, respectively—signaling reduced expectations while maintaining targets above the quoted share price. Read More.
• Negative Sentiment: Q3 adjusted earnings of $1.72 per share and revenue of $908.55 million both missed analyst estimates. Axon’s 2026 revenue outlook is now $3.6 billion versus a $3.7 billion consensus; Q4 revenue guidance of $990 million–$1.0 billion is also below expectations of about $1.1 billion. Federal drone deployment delays are weighing on the outlook. Read More.
• Negative Sentiment: Axon faces a class-action lawsuit concerning its AI-powered license-plate surveillance network, adding legal and reputational uncertainty. Read More.

About Axon Enterprise

Axon Enterprise, Inc develops technology and connected products for public safety organizations. The company’s portfolio includes TASER conducted-energy weapons, body-worn cameras, in-car cameras, and related hardware designed to support law enforcement, corrections, security, and other emergency-response professionals.

Axon also provides cloud-based software for managing digital evidence, records, workflows, real-time operations, investigations, and communications. Its platform is intended to connect hardware, software, and services across the public-safety ecosystem, helping agencies collect, store, analyze, and share operational information.

The company was founded in 1993 as TASER International by Rick Smith and Tom Smith and adopted the name Axon Enterprise in 2017 as it expanded beyond conducted-energy weapons into a broader technology platform.